Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

64.76
-1.6600-2.50%
Volume:331.10K
Turnover:21.42M
Market Cap:5.36B
PE:8.32
High:65.29
Open:64.78
Low:64.00
Close:66.42
52wk High:87.50
52wk Low:35.95
Shares:82.77M
Float Shares:72.98M
Volume Ratio:0.32
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.78
EPS(LYR):7.78
ROE:-7740.12%
ROA:23.26%
PB:-26.11
PE(LYR):8.32

Loading ...

PTC Therapeutics price target raised to $80 from $68 at JPMorgan

TIPRANKS
·
Nov 05, 2025

Stock Track | PTC Therapeutics Soars 5.58% Pre-Market on Strong Q3 Results and Successful Drug Launch

Stock Track
·
Nov 05, 2025

Stock Track | PTC Therapeutics Surges 5.58% Pre-market on Strong Q3 Results and Successful Drug Launch

Stock Track
·
Nov 05, 2025

U.S. RESEARCH ROUNDUP-ADM, Pinterest, UL Solutions

Reuters
·
Nov 05, 2025

PTC Therapeutics Inc : TD Cowen Raises Target Price to $63 From $50

THOMSON REUTERS
·
Nov 05, 2025

PTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation

Reuters
·
Nov 05, 2025

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2025 Revenue Range $750M - $800M, vs. FactSet Est of $1.73B

MT Newswires Live
·
Nov 05, 2025

Earnings Flash (PTCT) PTC Therapeutics Posts Q3 EPS $0.20, vs. FactSet Est of $1.13 Loss

MT Newswires Live
·
Nov 05, 2025

Stock Track | PTC Therapeutics Soars 6.79% After-Hours on Strong Q3 Earnings Beat

Stock Track
·
Nov 05, 2025

Stock Track | PTC Therapeutics Soars 6.79% After-Hours on Surprise Q3 Profit, Strong Revenue, and Successful Drug Launch

Stock Track
·
Nov 05, 2025

Rare‑diseases biopharma firm PTC Therapeutics' Q3 revenue rises to $211 mln

Reuters
·
Nov 05, 2025

PTC Therapeutics Q3 EPS $0.20 Beats $(1.42) Estimate, Sales $211.007M Beat $185.251M Estimate

Benzinga
·
Nov 05, 2025

BRIEF-PTC Therapeutics Q3 Net Income USD 15.896 Million

Reuters
·
Nov 05, 2025

PTC Therapeutics Inc - Narrows 2025 Revenue Guidance to $750-$800M

THOMSON REUTERS
·
Nov 05, 2025

PTC Therapeutics Inc expected to post a loss of $1.37 a share - Earnings Preview

Reuters
·
Nov 01, 2025

PTC Therapeutics Director Emma Reeve Reports Disposal of Common Shares

Reuters
·
Nov 01, 2025

How Investors May Respond To PTC Therapeutics (PTCT) Analysts' Optimism on Sephience Launch Momentum

Simply Wall St.
·
Oct 31, 2025

PTC Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Oct 29, 2025

U.S. RESEARCH ROUNDUP- BCB Bancorp, Cadence Design Systems, Intellia Therapeutics

Reuters
·
Oct 28, 2025

BRIEF-PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Oct 28, 2025